Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Liabilities and Shareholders Equity: 2021-2025

Historic Liabilities and Shareholders Equity for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $362.7 million.

  • Amylyx Pharmaceuticals' Liabilities and Shareholders Equity rose 44.68% to $362.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $970.6 million, marking a year-over-year decrease of 36.05%. This contributed to the annual value of $193.6 million for FY2024, which is 62.58% down from last year.
  • Amylyx Pharmaceuticals' Liabilities and Shareholders Equity amounted to $362.7 million in Q3 2025, which was up 86.41% from $194.6 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $517.5 million during Q4 2023, and its lowest value of $105.6 million during Q4 2021.
  • In the last 3 years, Amylyx Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $362.7 million in 2025 and averaged $347.0 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Liabilities and Shareholders Equity surged by 270.64% in 2022 and then tumbled by 62.58% in 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $105.6 million in 2021, then soared by 270.64% to $391.5 million in 2022, then surged by 32.19% to $517.5 million in 2023, then plummeted by 62.58% to $193.6 million in 2024, then soared by 44.68% to $362.7 million in 2025.
  • Its Liabilities and Shareholders Equity was $362.7 million in Q3 2025, compared to $194.6 million in Q2 2025 and $219.7 million in Q1 2025.